Dr. Aleksandar Obradovic received his M.D/Ph.D. from Columbia University in 2023, graduating in the Department of Systems Biology under the joint mentorship of Dr. Andrea Califano and Dr. Charles Drake. Dr. Obradovic is currently an associate research scientist in the Columbia Department of Medicine – Division of Experimental Therapeutics, and a clinician at New York Presbyterian Hospital.
The Obradovic Lab focuses on development of novel computational approaches for analysis of gene expression, TCR-Seq, and spatial data, at the bulk and single-cell level. We apply these tools across clinical trial data toward an improved understanding of the immunological mechanisms of resistance to checkpoint inhibitors, with an aim to infer and prioritize synergistic combination-therapies for improving cancer treatment outcomes.
Dr. Aleksandar Obradovic received his M.D/Ph.D. from Columbia University in 2023, graduating in the Department of Systems Biology under the joint mentorship of Dr. Andrea Califano and Dr. Charles Drake. Dr. Obradovic is currently an associate research scientist in the Columbia Department of Medicine – Division of Experimental Therapeutics, and a clinician at New York Presbyterian Hospital.
The Obradovic Lab focuses on development of novel computational approaches for analysis of gene expression, TCR-Seq, and spatial data, at the bulk and single-cell level. We apply these tools across clinical trial data toward an improved understanding of the immunological mechanisms of resistance to checkpoint inhibitors, with an aim to infer and prioritize synergistic combination-therapies for improving cancer treatment outcomes.